To evaluate the clinical relevance of IFN‐I signaling and cancer cell resistance to NK cells, we measured the levels of IFNβ and HLA‐I expression in human breast tumor biopsies via immunohistochemistry. The gene discussed is IFNB1; the disease is breast neoplasm.